Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

  • Barber L
  • Sandhu S
  • Chen L
 et al. 
  • 80

    Readers

    Mendeley users who have this article in their library.
  • 105

    Citations

    Citations of this article.

Abstract

PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality. Although clinical resistance to PARPi has been described, the mechanism underlying this has not been elucidated. Here, we investigate tumour material from patients who had developed resistance to the PARPi olaparib, subsequent to showing an initial clinical response. Massively parallel DNA sequencing of treatment-naive and post-olaparib treatment biopsies identified tumour-specific BRCA2 secondary mutations in olaparib-resistant metastases. These secondary mutations restored full-length BRCA2 protein, and most likely cause olaparib resistance by re-establishing BRCA2 function in the tumour cells.

Author-supplied keywords

  • BRCA
  • PARP inhibitor
  • cancer
  • drug resistance
  • massively parallel sequencing
  • secondary mutation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Louise J. Barber

  • Shahneen Sandhu

  • Lina Chen

  • James Campbell

  • Iwanka Kozarewa

  • Kerry Fenwick

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free